SAB Biotherapeutics Inc
SABS
查看详细走势图
4.170USD
+0.190+4.77%
收盘 02/06, 16:00（美东）报价延迟15分钟
198.05M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.77%
5天
-5.01%
1月
+5.04%
6月
+87.00%
今年开始到现在
+11.50%
1年
+102.43%
查看详细走势图
TradingKey SAB Biotherapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
SAB Biotherapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名87/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价9.38。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
SAB Biotherapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
SAB Biotherapeutics Inc亮点
亮点风险
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
业绩增长期
公司处于发展阶段，最新年度总收入1.32M美元
利润高增长
公司净利润处于行业前列，最新年度总收入1.32M美元
估值低估
公司最新PE估值-8.36，处于3年历史低位
机构加仓
最新机构持股29.75M股，环比增加46.68%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值80.84K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.75
分析师目标
根据
8
位分析师
买入
评级
9.375
目标均价
+121.63%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
SAB Biotherapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
SAB Biotherapeutics Inc简介
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
公司代码SABS
公司SAB Biotherapeutics Inc
CEOReich (Samuel J)
网址https://www.sab.bio/
相关品种
